RemeGen’s Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren’s Syndrome

RemeGen Co. Ltd., a commercial-stage biotechnology company, obtained Fast Track Designation by the United States Food and Drug Administration recently for its innovative BLyS/APRIL dual-target fusion protein drug, Telitacicept, independently developed by RemeGen for the treatment of patients with primary Sjögren’s syndrome.